Efficacy of PosBion® Postbiotic Supplementation in Adults With Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain and altered bowel habits, often associated with impaired intestinal barrier function, low-grade inflammation, and dysregulation of the gut-brain axis. Postbiotics have emerged as a promising therapeutic approach due to their immunomodulatory, anti-inflammatory, and gut barrier-protective properties. This completed single-arm, open-label clinical study evaluated the efficacy of PosBion® postbiotic supplementation in adults with IBS over a 12-week intervention period. The study assessed changes in IBS symptom severity, quality of life, gastrointestinal health, inflammatory biomarkers, intestinal barrier integrity, mucosal immunity, oxidative stress, and gut-brain axis biomarkers using validated questionnaires and salivary biomarker analyses.

NCT Number	NCT07699926
Lead Sponsor	My Myracle Sdn.Bhd Collaborators: UCSI University
Conditions	IBS (Irritable Bowel Syndrome), IBD (Inflammatory Bowel Disease), Gut Health
Enrollment	55 participants
Start Date	2026-01-01
Primary Completion	2026-05-31 (estimated)
Study Completion	2026-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-07-14